SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED

Ratings Shanghai HeartCare Medical Technology Corporation Limited

Equities

6609

CNE100004MN5

Market Closed - Hong Kong S.E. Other stock markets 04:09:00 2024-05-03 am EDT			5-day change	1st Jan Change
19.36 ^HKD	+7.92%		+8.04%	-34.92%

Mar. 28	Shanghai HeartCare Medical Technology Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Shanghai HeartCare Offloads Stake in Medical Device Developer Shenji Medical	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
With an expected P/E ratio at 968 and 20.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED	-34.92%	94.53M	-
ABBOTT LABORATORIES	-3.79%	184B	C+
MEDTRONIC PLC	-0.84%	108B	C
BECTON, DICKINSON AND COMPANY	-3.75%	67.8B	A
DEXCOM, INC.	+3.45%	51.05B	B-
CENCORA, INC.	+9.04%	44.67B	B-
HOYA CORPORATION	+3.40%	41.78B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+3.21%	26.78B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.66%	26.59B	A-
TERUMO CORPORATION	+15.23%	25.86B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes